This description is related to implantable neural stimulators.
A variety of therapeutic intra-body electrical stimulation techniques can treat neuropathic conditions. These techniques may utilize a subcutaneous battery operated implantable pulse generator (IPG) connected to one or more implantable wired leads. These leads have numerous failure modes, including mechanical dislodgement, impingement of the lead-extension tubing, infection, and uncomfortable irritation from the IPG and extension tubing. Various types of spinal cord stimulation (SCS) leads have been used to provide therapeutic pain relief. These lead configurations often include cylindrical percutaneous leads and paddle lead form factors. Cylindrical percutaneous leads typically have diameters in the range of 1.3 mm and contain a number of circular electrodes used for effectiveness testing during a trial implant period, and in many cases for the permanent implantation. Paddle leads, however, contain electrodes with a greater surface area directionally targeted for control over the excitation of the nerve bundles and may require surgical laminotomy.
Some embodiments provide an implantable neural stimulator wireless lead. The wireless lead includes: an enclosure; the enclosure housing; a) one or more electrodes configured to apply one or more electrical pulses to a neural tissue; b) a first antenna configured to receive, from a second antenna through electrical radiative coupling, an input signal containing electrical energy, the second antenna being physically separate from the implantable neural stimulator lead; c) one or more circuits electrically connected to the first antenna, the circuits configured to create the one or more electrical pulses suitable for stimulation of the neural tissue using the electrical energy contained in the input signal, and supply the one or more electrical pulses to the one or more electrodes, wherein the enclosure is shaped and arranged for delivery into a subject's body through an introducer or a needle.
Embodiments may include one or more features. For example, a portion of the enclosure may leave the electrodes in a non-direct contact with the neural tissue after the lead has been delivered into the subject's body. The enclosure can be semi-cylindrical in shape and the electrodes may include at least one directional electrode that directs a current path associated with the one or more electrical pulses to a direction that is substantially perpendicular to the neural tissue. The electrodes may include a semi-cylindrical array of electrodes. The electrodes may be made of at least one of: platinum, platinum-iridium, gallium-nitride, titanium-nitride, iridium-oxide, or combinations thereof. The electrodes can include two to sixteen electrodes, each having a longitudinal length between 1.0 and 6.0 mm and a width between 0.4 and 3.0 mm. The electrodes are spaced between 1 mm to 6 mm apart and have a combined surface area of between 0.8 mm2 to 60.00 mm2.
The lead may be a paddle-style lead. Specifically, the lead can be a paddle lead with a height between 1.3 mm and 2.0 mm, and a width between 2.0 mm and 4.0 mm. The lead can be shaped concavely to secure a lateral position on the neural tissue after the lead has been delivered into the subject's body. The lateral position may be with regard to a dorsal aspect of the subject's spinal cord. For example, the lead has a concave profile between 1.0 mm and 1.5 mm, and a concave edge between 0.2 mm and 0.3 mm.
The lead can be delivered into an epidual space of a subject's body. The delivery can be through a needle, such as, for example, a tuohy needle, no larger than gauge 14. The lead may be delivered to treat a neural tissue associated with the spinal column.
The enclosure can further house a lumen to operate a navigating stylet during delivery of the enclosure. The enclosure may further include a distal tip. The distal tip can be rounded with a length of between 0.5 mm and 2.0 mm. The distal tip can also be pointed with a length of between 2.0 and 6.0 mm. The enclosure may have an external coating of bio-compatible polymer, the polymer includes at least one of: polymethymethacrylate (PMMA), polydimethylsiloxane (PDMS), parylene, polyurethance, polytetrafluoroethylene (PTFE), or polycarbonate. The enclosure may further have an external coating of silicone elastomer. The enclosure can further house antenna coupling contacts, the antenna contacts being electrically connected to the antennas and the circuit and configured to couple the antenna with the surrounding tissue. The antenna coupling contacts can include two to eight antenna-coupling pairs. The antenna coupling contacts may be located proximal, relative to the electrodes, in the enclosure. The antenna coupling contacts can each have a longitudinal length of between 1.0 mm and 6.0 mm, and a width of between 1.0 mm to 2.5 mm. The antenna coupling contacts can be spaced between 30 mm and 80 mm apart. At least one of the antennas can be constructed as a conductive trace contained on one of the circuits. At least one of the antennas can be fabricated as a conductive wire connected to one of the circuits. The circuits can be flexible circuits. The flexible circuits are capable of undergoing a bend radius of under 0.5 mm. The flexible circuits can be placed proximal, relative to the electrodes, in the enclosure. The flexible circuits can include a waveform conditioning circuit.
Some embodiments provide a method of treating neurological pain. The method includes: providing an implantable neural stimulator lead including an enclosure that houses: one or more electrodes; a first antenna configured to receive, from a second antenna and through electrical radiative coupling, an input signal containing electrical energy, the second antenna being physically separate from the implantable neural stimulator lead; one or more flexible circuits electrically connected to the first antenna, the flexible circuits configured to: create the one or more electrical pulses suitable to be applied at the electrodes using the electrical energy contained in the input signal; and supply the one or more electrical pulses to the one or more electrodes, and implanting the neural stimulator lead into a subject's body through an introducer or a needle.
Embodiments may include one or more of the following features. For example, a portion of the enclosure may leave the electrodes in a non-direct contact with a neural tissue after the lead has been implanted into the subject's body. The electrodes can include at least one directional electrode that confines a current path associated with the one or more electrical pulses in a direction substantially perpendicular to the neural tissue. The needle can be a tuohy needle no larger than gauge 14.
Spinal cord stimulation may treat chronic neuropathic pain, especially low back pain and radiculopathy, vascular insufficiency in the feet or hands, angina, and more. In various implementations, a neural stimulation system can send electrical stimulation to targeted nerve tissue with neither cables nor inductive coupling to power the passive implanted stimulator. This can be used to treat pain or a variety of other modalities. The targeted nerve tissues may be, for example, in the spinal column including the spinothalamic tracts, dorsal horn, dorsal root ganglia, dorsal roots, dorsal column fibers, and peripheral nerves bundles leaving the dorsal column or brainstem, as well as any cranial nerves, abdominal, thoracic, or trigeminal ganglia nerves, nerve bundles of the cerebral cortex, deep brain and any sensory or motor nerves.
The neural simulation system can include an implantable lead that includes an enclosure that houses one or more conductive antennas (for example, dipole or patch antennas), internal circuitry for frequency waveform and electrical energy rectification, and one or more electrode pads allowing for neural stimulation of tissue. The neural stimulation system may receive microwave energy from an external source. The implantable lead may be 1.3 mm diameter or smaller. Particular implementations of the circuitry, antennas and pads are described in PCT Application PCT/US2012/023029, now expired while the US counterpart published as US-2012-0283800-A1 and issued as U.S. Pat. No. 9,409,030, which is incorporated herein by reference.
In various embodiments, the implantable lead is powered wirelessly (and therefore does not require a wired connection) and contains the circuitry necessary to receive the pulse instructions from a source external to the body. For example, various embodiments employ internal dipole (or other) antenna configuration(s) to receive RF power through electrical radiative coupling. This can allow such leads to produce electrical currents capable of stimulating nerve bundles without a physical connection to an implantable pulse generator (IPG) or use of an inductive coil. This can be advantageous relative to designs that employ inductive coils to receive RF power through inductive coupling and then transfer the received power to a large IPG device for recharging, particularly since the large IPG device for recharging can be as large as 100 mm by 70 mm.
Furthermore, the electrical radiative coupling mechanism (for example, a dipole antenna) can be utilized to improve the form factor of a wireless lead and allow for miniature diameters, as small as 30 microns. For example, some implementations of the wireless lead, such as those discussed in association with
Electrical radiative coupling also allows for the transmission and reception of energy at greater depths with less degradation in efficiency than inductive coil techniques. This can provide an advantage over devices that employ inductive coupling since the efficiency of such implants is highly dependent on the distance separating the external transmitter coil and the implanted receiver coil.
Various embodiments can also include distinct advantages over wired leads in regards to ease of insertion, cross connections, elimination of extension wires, and no requirement for an implantable pulse generator in order to administer a chronic therapy. Various implementations also may have an associated lower overall cost compared to existing implantable neural modulation systems due to the elimination of the implantable pulse generator, and this may lead to wider adoption of neural modulation therapy for patients as well as reduction in overall cost to the healthcare system.
In some embodiments, the tubing 201 contains a lumen for a stylet (otherwise referred to as an “injector lead wire,” a “guide-wire,” a “navigation wire,” or “a steer wire”), which can be used for placing the lead 200. The stylet may be made of metal and can provide steerability strength during implantation of the wireless paddle lead 200. After the wireless paddle lead 200 has been successfully deployed, the metal stylet may be removed. As will be discussed in association with
In certain embodiments, wireless paddle leads 200, cylindrical leads 400 or semi-cylindrical leads 300 may be adapted to be located within the epidural space of the spinal column, near or on the dura of the spinal column, in tissue in close proximity to the spinal column, in tissue located near the dorsal horn, dorsal root ganglia, dorsal roots, dorsal column fibers and/or peripheral nerve bundles leaving the dorsal column of the spine.
In certain embodiments, wireless paddle leads 200, cylindrical leads 400 or semi-cylindrical leads 300 can be adapted to be placed and secured to stimulate nerves leaving the spinal column for the treatment of a variety of conditions, such as, for example, pain, angina, peripheral vascular disease, gastrointestinal disorders. In other embodiments, wireless paddle leads 200 can be adapted to treat other conditions via neural stimulation of nerve bundles emanating from the spine. “Spinal cord tissue” and “nerve bundles emanating from the spine” generally refer to, without limitation, the nerve bundles ranging from spinal column levels C1 to L5, dorsal horn, dorsal root ganglia, dorsal roots, dorsal column fibers and peripheral nerve bundles leaving the dorsal column.
The various leads described herein may include anywhere from one to sixteen electrodes, any of which can be designated by the programmer as either a cathode or an anode. For example, electrodes 203 can include multiple cathodes coupled to the targeted tissue as well as at least one anode. The electrode array can receive electrical stimulation waveform pulses ranging from 0 to 10V peak amplitude at a pulse width reaching up to a maximum of 1 millisecond. The polarity of the electrodes can produce various volume conduction distributions from the cathodes to the anodes to inhibit or excite surrounding nerve tissue, which may include A-δ and/or primary or secondary c-fiber afferents. To minimize electrode impedance, the electrodes may be made of a conductive, corrosion resistant, biocompatible material such as, for example, platinum, platinum-iridium, gallium-nitride, titanium-nitride, or iridium-oxide.
Excluding the electrodes 203, which are coupled to the surrounding tissue, the remaining portions of the wireless lead embodiments described herein may be insulated from surrounding body tissue partially or totally by an external coating layer of biocompatible dielectric material with a low dielectric constant. Materials with rigidity similar to that of tissue can be used to reduce the risk of migration and the development of fibrous scar tissue. Such fibrous scar tissue can increase electrode-tissue impedance. If the electrode-tissue impedance can be kept low, less energy may be consumed to achieve stimulation of the targeted tissues.
In certain embodiments, the wireless paddle lead 200 can have a rounded tip 211 at the distal end. Rounded tip 211 can be a non-conductive tip. Rounded tip 211 can have a length of between 0.5 mm and 2.0 mm, and a smooth finish for navigating the lead through the epidural space.
In certain embodiments, the wireless paddle lead 200 can have a pointed tip 219 at the distal end. Pointed tip 219 can be a non-conductive tip. Pointed tip 219 can have a length of between about 2.0 mm and about 6.0 mm. Pointed tip 219 can enhance the steering capability when the wireless paddle 200 is being deployed.
In certain embodiments, at least one additional wireless lead may be placed in parallel or offset with the initial wireless lead. In some embodiments, the wireless leads may be activated sequentially. In other embodiments, wireless leads can be activated simultaneously.
For example, antenna 208 may be coupled to tissue through the antenna coupling contacts 222 located on the ventral side of the wireless paddle lead 200. The antenna can be, for example, a dipole antenna. Some embodiments may have only one dipole antenna, other embodiments may have multiple antennas of any given length. For example, without limitation, some embodiments may have between two and ten dipole antennas, while other embodiments can have more than ten dipole antennas or more than twenty dipole antennas. In some embodiments, a dipole antenna can range from about 100 microns to about 10 cm in length. In other embodiments, an antenna can consist of any linear dipole configuration ranging from about 20 microns to about 3 mm in thickness. The antenna 208 may also be a folded dipole antenna instead of straight dipole antenna.
Antenna 208 may be configured to receive RF energy from exterior antennas. RF wave propagation energy is divided into two regions, the radiative region and the reactive region. The radiative region is within 2D2/λ and the radiated power varies with distance from the antenna. For a short dipole antenna, the reactive component is approximately λ/2π. The induced field for antennas placed in biological tissue is a function of body geometry, tissue properties, and the exposure conditions. The efficiency of the RF waveform inside a lossy media, such as body tissue, is attenuated by the tissue as it propagates. To increase the power efficiency of a small antenna in lossy matter, the dipole antenna configuration can be optimized at high frequencies to minimize losses, such as, for example, from about 800 MHz to 5.8 GHz or greater.
The antenna coupling contacts 222 in certain embodiments may have a longitudinal length between about 1.0 mm and about 6.0 mm from the distal tip toward the proximal tip and a width of between about 1.0 mm to about 2.5 mm. The spacing between the antenna coupling contacts 222 may be between about 30 mm and about 80 mm. The antenna coupling contracts 222 may improve the efficiency of the radiative coupling between internal antenna 208 and the antenna(s) (not depicted) located externally to the body. The antenna coupling contracts 222 may be made of noncorrosive metals, such as, for example, platinum, platinum-iridium, gallium-nitride, titanium-nitride, or iridium-oxide.
Antenna coupling contacts 222 may be connected by conducting wires 210 to the antenna(s) 208 and the waveform conditioning circuit 209. Waveform conditioning circuitry 209 may include, for example electronic components such as, for example diodes, resistors and capacitors. Waveform conditioning circuitry 209 can use the incoming energy to provide a stimulation waveform to the electrodes for excitation of nerve tissue. In some embodiments, frequencies from about 800 MHz to about 5.8 GHz may be received by the implanted antenna 208. The stimulating waveform released into the tissue from electrodes 203 is rectified to provide waveforms at lower frequencies, e.g., at typically from about 5 Hz to about 1000 Hz.
Waveform conditioning circuitry 209 is configured to rectify the waveform signal received by implanted antenna 208. Waveform conditioning circuitry 209 may also have charge balance microelectronics to prevent the corrosion of the electrodes. To minimize reflection of the energy back from the electrodes into the circuitry, waveform-conditioning circuitry 209 may include isolation circuits to block high frequency signals.
In some embodiments, the wireless leads described herein may have multiple layers. These layers can include, without limitation, encasing material close to the electrodes with a biocompatible compound that elicits minimal scar tissue formation. In addition, layers may include polymers such as, without limitation, polymethymethacrylate (PMMA), polydimethylsiloxane (PDMS), parylene, polyurethane, polytetrafluoroethylene (PTFE), or polycarbonate. Another layer of a material that may be included contains a small relative permeability and low conductivity located above the antennas 208 to allow for optimal coupling with an exterior antenna (not depicted). Yet another layer can comprise a coating of a silicone elastomer to assist in preventing migration of the wireless lead to the surrounding tissue.
The wireless semi-cylindrical lead 300 may include between two to eight antenna coupling contacts 304, as illustrated in association with
Embodiments of wireless leads described herein can have a larger surface area directed towards the dura mater than existing percutaneous leads. This increased surface area can lower the tissue to electrode impedance values and can lead to larger currents for stimulation.
One or more flexible circuits 206 may be used to carry various parts of the electronic components. For instance, the flexible circuits 206 may include the waveform conditioning circuitry 209 and implantable antenna(s) 208. The flex circuit may also include portions of the wires 210, which connect the electronics, such as circuitry 209, to the electrodes 203. The flexible circuits 206 may be between about 15 mm and about 90 mm long, and about 0.7 mm and about 2.0 mm wide. The total height of the flexible circuit 206 with the waveform conditioning circuitry 209 may be between about 0.2 mm and about 0.4 mm. The flexible circuit 206, when placed inside of the cylindrical wireless lead 400 may undergo a bend radius under about 0.5 mm. As illustrated in
Various implementations of the technology may allow placement of wireless lead in the epidural space, between the dura mater and arachnoid membranes, or subdurally in the intrathecal space, where significant reactions and scarring would be minimized. Insertion in any of these locations may be done by injecting the device from a smaller gauge needle (e.g., 14 to 22-gauge needle or out of a cannula steered to the proper position by a removable stylet). In some implementations, once in position, no further skin incisions or placement of extensions, receivers or implanted pulse generators are needed. Various implementations of the wireless neural modulation system may have significant advantages due to the small size and lack of extension wires for transfer of energy, allowing placement with minimal trauma and long term effective therapy in places where larger implantable devices could cause more scar tissue and tissue reactions that may affect efficacy and safety.
A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made. Accordingly, other implementations are within the scope of the following claims.
This application is a continuation of U.S. application Ser. No. 16/275,666, filed Feb. 14, 2019, now allowed, which is a continuation of U.S. application Ser. No. 15/709,962, filed Sep. 20, 2017, now U.S. Pat. No. 10,238,874, issued Mar. 26, 2019, which is a continuation of U.S. application Ser. No. 14/972,386, filed on Dec. 17, 2015, now U.S. Pat. No. 9,789,314, issued Oct. 17, 2017, which is a continuation of U.S. application Ser. No. 14/045,764, filed on Oct. 3, 2013, now U.S. Pat. No. 9,220,897, issued on Dec. 29, 2015, which is a continuation of PCT Application No. PCT/US2012/032200, international filing date Apr. 4, 2012, which claims the benefit of U.S. Provisional Patent Application 61/471,496, filed Apr. 4, 2011. All prior applications are hereby incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
2990547 | McDougal | Jun 1961 | A |
3662758 | Glover | May 1972 | A |
3663758 | Erbert | May 1972 | A |
3727616 | Lenzkes | Apr 1973 | A |
4057069 | Dorffer et al. | Nov 1977 | A |
4102344 | Conway et al. | Jul 1978 | A |
4223679 | Schulman et al. | Sep 1980 | A |
4494950 | Fischell | Jan 1985 | A |
4524774 | Hildebrandt | Jun 1985 | A |
4525774 | Kino et al. | Jun 1985 | A |
4532930 | Crosby | Aug 1985 | A |
4561443 | Hogrefe et al. | Dec 1985 | A |
4592359 | Galbraith | Jun 1986 | A |
4612934 | Borkan | Sep 1986 | A |
4628933 | Michelson | Dec 1986 | A |
4665896 | LaForge | May 1987 | A |
4726378 | Kaplan | Feb 1988 | A |
4736747 | Drake | Apr 1988 | A |
4736752 | Munck | Apr 1988 | A |
4741339 | Harrison et al. | May 1988 | A |
4750499 | Hoffer | Jun 1988 | A |
4793353 | Borkan | Dec 1988 | A |
4837049 | Byers et al. | Jun 1989 | A |
4926879 | Sevrain | May 1990 | A |
4947844 | McDermott | Aug 1990 | A |
5058581 | Silvian | Oct 1991 | A |
5070535 | Hochmair et al. | Dec 1991 | A |
5193539 | Schulman et al. | Mar 1993 | A |
5262793 | Sperry | Nov 1993 | A |
5314458 | Najafi et al. | May 1994 | A |
5343766 | Lee | Sep 1994 | A |
5358514 | Schulman et al. | Oct 1994 | A |
5411535 | Fujii et al. | May 1995 | A |
5583510 | Ponnapalli et al. | Dec 1996 | A |
5591217 | Barreras | Jan 1997 | A |
5626630 | Markowitz et al. | May 1997 | A |
5735887 | Barreras, Sr. et al. | Apr 1998 | A |
5769877 | Barreras | Jun 1998 | A |
5861019 | Sun et al. | Jan 1999 | A |
5991664 | Seligman | Nov 1999 | A |
5995874 | Borza | Nov 1999 | A |
6141588 | Cox et al. | Oct 2000 | A |
6164284 | Shulman et al. | Dec 2000 | A |
6175752 | Say et al. | Jan 2001 | B1 |
6350335 | Hampel et al. | Feb 2002 | B1 |
6364889 | Kheiri et al. | Apr 2002 | B1 |
6415184 | Ishikawa et al. | Jul 2002 | B1 |
6445953 | Bulkes et al. | Sep 2002 | B1 |
6445955 | Michelson et al. | Sep 2002 | B1 |
6458157 | Suaning | Oct 2002 | B1 |
6463336 | Mawhinney | Oct 2002 | B1 |
D466487 | Wada et al. | Dec 2002 | S |
6516227 | Meadows et al. | Feb 2003 | B1 |
D474982 | Wilson | May 2003 | S |
6564807 | Schulman et al. | May 2003 | B1 |
6611715 | Boveja | Aug 2003 | B1 |
6615081 | Boveja | Sep 2003 | B1 |
6647296 | Fischell et al. | Nov 2003 | B2 |
6662052 | Sarwal et al. | Dec 2003 | B1 |
6684104 | Gordon et al. | Jan 2004 | B2 |
6690974 | Archer et al. | Feb 2004 | B2 |
6889086 | Mass et al. | May 2005 | B2 |
6895280 | Meadows et al. | May 2005 | B2 |
6972727 | West et al. | Dec 2005 | B1 |
7003350 | Denker et al. | Feb 2006 | B2 |
7027874 | Sawan et al. | Apr 2006 | B1 |
7110823 | Whitehurst et al. | Sep 2006 | B2 |
D529402 | Burton | Oct 2006 | S |
7177690 | Woods et al. | Feb 2007 | B2 |
7214189 | Zdeblick | May 2007 | B2 |
7277728 | Kauhanen | Oct 2007 | B1 |
7283875 | Larsson | Oct 2007 | B2 |
7317947 | Wahlstrand et al. | Jan 2008 | B2 |
7436752 | He | Oct 2008 | B2 |
7450992 | Cameron | Nov 2008 | B1 |
7471257 | Candal et al. | Dec 2008 | B2 |
7489248 | Gengel et al. | Feb 2009 | B2 |
7616991 | Mann et al. | Nov 2009 | B2 |
7620451 | Demarais | Nov 2009 | B2 |
7630771 | Cauller | Dec 2009 | B2 |
7664552 | Wahlstrand et al. | Feb 2010 | B2 |
D612543 | Marseille | Mar 2010 | S |
7729781 | Swoyer et al. | Jun 2010 | B2 |
7738964 | Von Arx et al. | Jun 2010 | B2 |
7741734 | Joannopoulos et al. | Jun 2010 | B2 |
7765013 | Blick et al. | Jul 2010 | B2 |
7853333 | Demarais | Dec 2010 | B2 |
7869885 | Begnaud et al. | Jan 2011 | B2 |
7894905 | Pless et al. | Feb 2011 | B2 |
7904170 | Harding | Mar 2011 | B2 |
7908014 | Schulman et al. | Mar 2011 | B2 |
7917226 | Nghiem et al. | Mar 2011 | B2 |
7939346 | Blick et al. | May 2011 | B2 |
D658302 | Nixon | Apr 2012 | S |
8170672 | Weiss et al. | May 2012 | B2 |
8242968 | Conrad et al. | Aug 2012 | B2 |
8320850 | Khlat | Nov 2012 | B1 |
8332040 | Winstrom | Dec 2012 | B1 |
8634928 | O'Drisco et al. | Jan 2014 | B1 |
D701504 | Christopher et al. | Mar 2014 | S |
D703204 | Riddiford et al. | Apr 2014 | S |
D714288 | Aumiller et al. | Sep 2014 | S |
8849412 | Perryman et al. | Sep 2014 | B2 |
8903502 | Perryman | Dec 2014 | B2 |
D721701 | Al-Nasser | Jan 2015 | S |
D725071 | Lee et al. | Mar 2015 | S |
D725072 | Kim et al. | Mar 2015 | S |
D725652 | Ishii | Mar 2015 | S |
D734330 | Huang et al. | Jul 2015 | S |
9199089 | Perryman et al. | Dec 2015 | B2 |
9220897 | Perryman et al. | Dec 2015 | B2 |
9242103 | Perryman et al. | Jan 2016 | B2 |
9254393 | Perryman et al. | Feb 2016 | B2 |
9409030 | Perryman et al. | Aug 2016 | B2 |
9566449 | Perryman et al. | Feb 2017 | B2 |
9757571 | Perryman | Sep 2017 | B2 |
9789314 | Perryman | Oct 2017 | B2 |
9925384 | Perryman et al. | Mar 2018 | B2 |
9974965 | Andresen et al. | May 2018 | B2 |
10238874 | Perryman | Mar 2019 | B2 |
10293169 | Perryman et al. | May 2019 | B2 |
10315039 | Perryman et al. | Jun 2019 | B2 |
10420947 | Larson et al. | Sep 2019 | B2 |
10471262 | Perryman et al. | Nov 2019 | B2 |
10953228 | Perryman et al. | Mar 2021 | B2 |
20010010662 | Saitou et al. | Aug 2001 | A1 |
20020058972 | Minogue et al. | May 2002 | A1 |
20020082668 | Ingman | Jun 2002 | A1 |
20020091420 | Minogue et al. | Jul 2002 | A1 |
20020095195 | Mass | Jul 2002 | A1 |
20020103513 | Minogue et al. | Aug 2002 | A1 |
20020123779 | Arx et al. | Sep 2002 | A1 |
20020128686 | Minogue et al. | Sep 2002 | A1 |
20020128693 | Minogue et al. | Sep 2002 | A1 |
20020133195 | Minogue et al. | Sep 2002 | A1 |
20030078633 | Firlik et al. | Apr 2003 | A1 |
20030114898 | Von Arx et al. | Jun 2003 | A1 |
20030114899 | Woods et al. | Jun 2003 | A1 |
20030139782 | Duncan et al. | Jul 2003 | A1 |
20030169207 | Beigel | Sep 2003 | A1 |
20030204224 | Torgerson et al. | Oct 2003 | A1 |
20040044385 | Fenn et al. | Mar 2004 | A1 |
20040059392 | Parramon et al. | Mar 2004 | A1 |
20040082979 | Tong et al. | Apr 2004 | A1 |
20040127942 | Yomtov et al. | Jul 2004 | A1 |
20040138723 | Malick et al. | Jul 2004 | A1 |
20040167587 | Thompson et al. | Aug 2004 | A1 |
20040176803 | Whelan et al. | Sep 2004 | A1 |
20040220621 | Zhou | Nov 2004 | A1 |
20040230263 | Samulski | Nov 2004 | A1 |
20040243208 | Jordan | Dec 2004 | A1 |
20050027207 | Westbrook et al. | Feb 2005 | A1 |
20050119716 | McClure et al. | Jun 2005 | A1 |
20050137668 | Khan | Jun 2005 | A1 |
20050245994 | Varrichio et al. | Nov 2005 | A1 |
20060001583 | Bisig | Jan 2006 | A1 |
20060003721 | Bisig | Jan 2006 | A1 |
20060047327 | Colvin et al. | Mar 2006 | A1 |
20060085039 | Hastings et al. | Apr 2006 | A1 |
20060085042 | Hastings et al. | Apr 2006 | A1 |
20060149331 | Man et al. | Jul 2006 | A1 |
20060161216 | Constance | Jul 2006 | A1 |
20060161225 | Sormann et al. | Jul 2006 | A1 |
20060178718 | Jordan | Aug 2006 | A1 |
20060206168 | Minogue et al. | Sep 2006 | A1 |
20060287686 | Cullen et al. | Dec 2006 | A1 |
20060289528 | Chiu et al. | Dec 2006 | A1 |
20070055322 | Forsberg et al. | Mar 2007 | A1 |
20070055324 | Thompson et al. | Mar 2007 | A1 |
20070066995 | Strother et al. | Mar 2007 | A1 |
20070100385 | Rawat | May 2007 | A1 |
20070100395 | Ibrahim | May 2007 | A1 |
20070100935 | Miyazaki et al. | May 2007 | A1 |
20070106337 | Errico et al. | May 2007 | A1 |
20070109208 | Turner | May 2007 | A1 |
20070112402 | Grill et al. | May 2007 | A1 |
20070123948 | Dal Molin | May 2007 | A1 |
20070156179 | S.E. | Jul 2007 | A1 |
20070208394 | King et al. | Sep 2007 | A1 |
20070213773 | Hill et al. | Sep 2007 | A1 |
20070213783 | Pless | Sep 2007 | A1 |
20070239224 | Bennett et al. | Oct 2007 | A1 |
20070254632 | Beadle et al. | Nov 2007 | A1 |
20070255223 | Phillips et al. | Nov 2007 | A1 |
20070255373 | Metzler et al. | Nov 2007 | A1 |
20070257636 | Phillips et al. | Nov 2007 | A1 |
20070265543 | VanSickle et al. | Nov 2007 | A1 |
20070265690 | Lichtenstein et al. | Nov 2007 | A1 |
20070288066 | Christman et al. | Dec 2007 | A1 |
20070293909 | Cowan et al. | Dec 2007 | A1 |
20080010358 | Jin | Jan 2008 | A1 |
20080046012 | Covalin et al. | Feb 2008 | A1 |
20080077184 | Denker et al. | Mar 2008 | A1 |
20080077188 | Denker et al. | Mar 2008 | A1 |
20080077189 | Ostroff | Mar 2008 | A1 |
20080103558 | Wenzel | May 2008 | A1 |
20080154217 | Carrez et al. | Jun 2008 | A1 |
20080161883 | Conor | Jul 2008 | A1 |
20080266123 | Ales et al. | Oct 2008 | A1 |
20080279896 | Heinen et al. | Nov 2008 | A1 |
20080281244 | Jacobs | Nov 2008 | A1 |
20090018599 | Hastings et al. | Jan 2009 | A1 |
20090099405 | Schneider et al. | Apr 2009 | A1 |
20090105784 | Massoud-Ansari | Apr 2009 | A1 |
20090105795 | Minogue et al. | Apr 2009 | A1 |
20090125091 | Schoenbach et al. | May 2009 | A1 |
20090132002 | Kieval | May 2009 | A1 |
20090132003 | Borgens et al. | May 2009 | A1 |
20090200985 | Zane et al. | Aug 2009 | A1 |
20090204170 | Hastings et al. | Aug 2009 | A1 |
20090234407 | Hastings et al. | Sep 2009 | A1 |
20090248112 | Mumbru et al. | Oct 2009 | A1 |
20090251101 | Phillips et al. | Oct 2009 | A1 |
20090270948 | Nghiem et al. | Oct 2009 | A1 |
20090270951 | Kallmyer | Oct 2009 | A1 |
20090292339 | Erickson | Nov 2009 | A1 |
20100010565 | Lichtenstein et al. | Jan 2010 | A1 |
20100053789 | Duric et al. | Mar 2010 | A1 |
20100114143 | Albrecht et al. | May 2010 | A1 |
20100114198 | Donofrio et al. | May 2010 | A1 |
20100125269 | Emmons | May 2010 | A1 |
20100125312 | Stevenson et al. | May 2010 | A1 |
20100137938 | Kishawi et al. | Jun 2010 | A1 |
20100168818 | Barror et al. | Jul 2010 | A1 |
20100174340 | Simon | Jul 2010 | A1 |
20100179449 | Chow et al. | Jul 2010 | A1 |
20100198039 | Towe | Aug 2010 | A1 |
20100198307 | Toy et al. | Aug 2010 | A1 |
20100231382 | Tayrani et al. | Sep 2010 | A1 |
20100234919 | Minogue et al. | Sep 2010 | A1 |
20100234922 | Forsell | Sep 2010 | A1 |
20100241051 | Dacey, Jr. et al. | Sep 2010 | A1 |
20100268298 | Moffitt et al. | Oct 2010 | A1 |
20100269339 | Dye et al. | Oct 2010 | A1 |
20100298742 | Perlman et al. | Nov 2010 | A1 |
20100331934 | McDonald et al. | Dec 2010 | A1 |
20110029043 | Frysz et al. | Feb 2011 | A1 |
20110040350 | Griffith | Feb 2011 | A1 |
20110054563 | Janzig et al. | Mar 2011 | A1 |
20110074342 | MacLaughlin | Mar 2011 | A1 |
20110077698 | Tsampazis et al. | Mar 2011 | A1 |
20110098583 | Pandia et al. | Apr 2011 | A1 |
20110106220 | DeGiorgio et al. | May 2011 | A1 |
20110120822 | Kondou et al. | May 2011 | A1 |
20110121822 | Parsche | May 2011 | A1 |
20110125214 | Goetz et al. | May 2011 | A1 |
20110130804 | Lin et al. | Jun 2011 | A1 |
20110144468 | Boggs et al. | Jun 2011 | A1 |
20110152750 | Dacey, Jr. et al. | Jun 2011 | A1 |
20110166630 | Phillips et al. | Jul 2011 | A1 |
20110172733 | Lima et al. | Jul 2011 | A1 |
20110190849 | Faltys et al. | Aug 2011 | A1 |
20110208266 | Minogue et al. | Aug 2011 | A1 |
20110245892 | Kast et al. | Oct 2011 | A1 |
20110276108 | Crowe et al. | Nov 2011 | A1 |
20120004708 | Chen et al. | Jan 2012 | A1 |
20120004709 | Chen et al. | Jan 2012 | A1 |
20120116477 | Crowe et al. | May 2012 | A1 |
20120143282 | Fukui et al. | Jun 2012 | A1 |
20120158407 | Forsell | Jun 2012 | A1 |
20120194399 | Bily et al. | Aug 2012 | A1 |
20120215218 | Lipani | Aug 2012 | A1 |
20120239107 | Kallmyer | Sep 2012 | A1 |
20120283800 | Perryman et al. | Nov 2012 | A1 |
20120302821 | Burnett | Nov 2012 | A1 |
20120330384 | Perryman et al. | Dec 2012 | A1 |
20130016016 | Lin et al. | Jan 2013 | A1 |
20130066400 | Perryman et al. | Mar 2013 | A1 |
20130079849 | Perryman et al. | Mar 2013 | A1 |
20130131752 | Rawat | May 2013 | A1 |
20130018439 | Chow et al. | Jun 2013 | A1 |
20130165991 | Kim | Jun 2013 | A1 |
20130226262 | Stevenson et al. | Aug 2013 | A1 |
20130310901 | Perryman et al. | Nov 2013 | A1 |
20140031837 | Perryman et al. | Jan 2014 | A1 |
20140047713 | Singh et al. | Feb 2014 | A1 |
20140058480 | Perryman et al. | Feb 2014 | A1 |
20140058481 | Perryman et al. | Feb 2014 | A1 |
20140169142 | Heck et al. | Jun 2014 | A1 |
20140266935 | Tankiewicz | Sep 2014 | A1 |
20140336727 | Perryman et al. | Nov 2014 | A1 |
20150182753 | Harris et al. | Jul 2015 | A1 |
20150321017 | Perryman et al. | Nov 2015 | A1 |
20160101287 | Perryman | Apr 2016 | A1 |
20160136438 | Perryman et al. | May 2016 | A1 |
20160136439 | Andresen et al. | May 2016 | A1 |
20160339258 | Perryman et al. | Nov 2016 | A1 |
20160361535 | Perryman et al. | Dec 2016 | A1 |
20160367825 | Perryman et al. | Dec 2016 | A1 |
20170036033 | Perryman et al. | Feb 2017 | A9 |
20180008828 | Perryman | Jan 2018 | A1 |
20180169423 | Larson et al. | Jun 2018 | A1 |
20180236248 | Perryman | Aug 2018 | A1 |
20180264277 | Perryman | Sep 2018 | A1 |
20190229771 | Lee et al. | Jul 2019 | A1 |
20190247660 | Perryman | Aug 2019 | A1 |
20190381327 | Perryman et al. | Dec 2019 | A1 |
20200016415 | Perryman et al. | Jan 2020 | A1 |
20200016416 | Perryman et al. | Jan 2020 | A1 |
20200222703 | Perryman et al. | Jul 2020 | A1 |
20210187311 | Perryman et al. | Jun 2021 | A1 |
20220088398 | Perryman et al. | Mar 2022 | A1 |
20220126105 | Perryman et al. | Apr 2022 | A1 |
Number | Date | Country |
---|---|---|
2734668 | Mar 2010 | CA |
1678370 | Oct 2005 | CN |
101185789 | May 2008 | CN |
101217320 | Jul 2008 | CN |
101352596 | Jan 2009 | CN |
101773701 | Jul 2010 | CN |
101842131 | Sep 2010 | CN |
201676401 | Dec 2010 | CN |
102120060 | Jul 2011 | CN |
2462981 | Jun 2001 | EP |
1588609 | Oct 2005 | EP |
2694154 | Jan 2018 | EP |
3403690 | Aug 2020 | EP |
2341347 | Jun 2010 | ES |
H10 509901 | Sep 1998 | JP |
2002524124 | Aug 2002 | JP |
2005531371 | Oct 2005 | JP |
2008023353 | Feb 2008 | JP |
2008161667 | Jul 2008 | JP |
2008528222 | Jul 2008 | JP |
2009523402 | Jun 2009 | JP |
2010534114 | Nov 2010 | JP |
201155912 | Mar 2011 | JP |
2011510787 | Apr 2011 | JP |
2012508624 | Apr 2012 | JP |
WO 9620754 | Jul 1996 | WO |
WO 2000013585 | Mar 2000 | WO |
WO 2004002572 | Jan 2004 | WO |
WO 2004004826 | Jan 2004 | WO |
WO 2006113802 | Oct 2006 | WO |
WO2006128037 | Nov 2006 | WO |
WO 2007059386 | May 2007 | WO |
WO 2007081971 | Jul 2007 | WO |
WO 2009015005 | Jan 2009 | WO |
WO 2010005746 | Jan 2010 | WO |
WO 2010051189 | May 2010 | WO |
WO 2010053789 | May 2010 | WO |
WO 2010057046 | May 2010 | WO |
WO 2010104569 | Sep 2010 | WO |
WO 2011079309 | Jun 2011 | WO |
WO 2012103519 | Aug 2012 | WO |
WO 2012138782 | Oct 2012 | WO |
WO 2013019757 | Feb 2013 | WO |
WO 2013025632 | Feb 2013 | WO |
WO 2013040549 | Mar 2013 | WO |
Entry |
---|
US 5,197,469 A, 03/1993, Adams (withdrawn) |
Extended European Search Report in European Appln No. 20738285.4, dated Aug. 17, 2022, 5 pages. |
Search Report in European Appln. No. 21164580.9, dated Oct. 22, 2021, 8 pages. |
U.S. Appl. No. 14/445,159, filed Nov. 13, 2014, Perryman et al. |
U.S. Appl. No. 29/478,687, filed Jan. 7, 2003, Perryman et al. |
CA Office Action in Canadian Appln. No. 2831138, dated Oct. 30, 2020, 4 pages. |
CN OA in Chinese Appln. No. 201710675346.5, dated Jun. 1, 2020, 11 pages (with English translation). |
EP European Search Report in European Appln. No. 12831083.6, dated Aug. 17, 2015, 9 pages. |
EP European Search Report in European Appln. No. 17208566.4, dated Sep. 26, 2018, 10 pages. |
EP Extended European Search Report in European Appln. No. 18150779.9, dated May 9, 2018, 7 pages. |
EP Extended European Search Report in European Appln. No. 20209052.8, dated Apr. 14, 2021, 7 pages. |
EP Office Action in European Appln. No. 12740011.7, dated Sep. 18, 2018, 5 pages. |
European Search Report in European Appln. No. 12767575.9, dated Jan. 11, 2018, 6 pages. |
European Search Report in European Appln. No. 19/186,209, dated Nov. 25, 2019, 9 pages. |
Extended European Search report in Appln. No. 12740011.7, dated Sep. 9, 2015, 6 pages. |
Extended European Search report in Appln. No. 12767575.9, dated Nov. 7, 2014, 7 pages. |
Extended European Search Report in Appln. No. 1281083.6, dated Aug. 17, 2015, 9 pages. |
Extended European Search report in Appln. No. 12819482.6, dated Apr. 28, 2015, 7 pages. |
Extended European Search Report in Appln. No. 12824347.4, dated Apr. 22, 2015, 6 pages. |
Extended European Search Report in Appln. No. 15793285.6, dated Dec. 12, 2017, 7 pages. |
Iannetta [online], “Nov. 2014 New Products: Wearable coil facilities positioning during prostate MRI,” Urology Times, retrieved on Nov. 10, 2014, retrieved from<URL: http://urologytimes.modernmedicine.com/urology-times/news/november-2014-new-products-wearable-coil-facilitates-positioning-during-prostate-mri?page=full>, 7 pages. |
IL Office Action in Israeli Appln. No. 256280.0, dated Sep. 16, 2020, 9 pages (with English Translation). |
O'Driscoll et al., “A mm-Sized implantable power receiver with adaptive link compensation,” Poster, Presented at IEEE International Solid-State Circuits Conference, Session 17, 2009, 3 pages. |
PCT International Preliminary Report on Patentability and Written Opinion in International Appln. No. PCT/US2012/023029, dated Jan. 28, 2014, 10 pages. |
PCT International Preliminary Report on Patentability and Written Opinion in International Appln. No. PCT/US2012/032200 dated Oct. 8, 2013, 11 pages. |
PCT International Preliminary Report on Patentability and Written Opinion in International Appln. No. PCT/US2012/048903, dated Mar. 25, 2014, 8 pages. |
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2013/077846, dated Jun. 30, 2015, 6 pages. |
PCT International Preliminary Report on Patentability issued in International Appl. No. PCT/US2012/055746, dated Jan. 2, 2013, 10 pages. |
PCT International Preliminary Report on Patentability issued in International Appln. No. PCT/US2012/050633, dated Feb. 18, 2014, 7 pages. |
PCT International Search Report and PCT Written Opinion of the International Searching Authority in International Appln. No. PCT/US2012/055746, dated Jan. 3, 2013, 11 pages. |
PCT International Search Report and the Written Opinion in Appln. No. PCT/US2012/048903 dated Oct. 10, 2012, 9 pages. |
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2012/023029, dated May 16, 2012, 10 pages. |
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2012/032200, dated Jul. 27, 2012, 12 pages. |
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2012/050633 dated Oct. 23, 2012, 7 pages. |
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2013/077846 dated Apr. 21, 2014, 10 pages. |
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/013155, dated Apr. 1, 2020, 8 pages. |
pharad.com [online], “Assembly, Wearable Antenna, 350-450 MHz, ”retrieved on Oct. 14, 2010, retrieved from URL< http://www.pharad.com/pdf/UHF-Wearable-Antenna-2D.pdf>, 1 page. |
Poon et al., “Optimal frequency for wireless power transmission into dispersive tissue,” IEEE Transactions on Antennas and Propagation, May 2010, 58(5):1739-1750. |
wirelessdesignmag.com [online], “Pharad at Forefront of LTE Antenna Innovation with Development of LTE Wearable Antenna,” retrieved on Aug. 12, 2012, retrieved from<URL:http://www.wirelessdesignmag.com/product-release/2013/08/pharad-forefront-lte-antenna-innovation-development-lte-wearable-antenna>, 3 pages. |
International Preliminary Report on Patentability in International Appln. No. PCT/US2020/013155, dated Jul. 22, 2021, 8 pages. |
Number | Date | Country | |
---|---|---|---|
20210275813 A1 | Sep 2021 | US |
Number | Date | Country | |
---|---|---|---|
61471496 | Apr 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16275666 | Feb 2019 | US |
Child | 17207904 | US | |
Parent | 15709962 | Sep 2017 | US |
Child | 16275666 | US | |
Parent | 14972386 | Dec 2015 | US |
Child | 15709962 | US | |
Parent | 14045764 | Oct 2013 | US |
Child | 14972386 | US | |
Parent | PCT/US2012/032200 | Apr 2012 | US |
Child | 14045764 | US |